| Trial ID: | L6483 |
| Source ID: | NCT00501683
|
| Associated Drug: |
Radiolabelled Gsk189075
|
| Title: |
A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Radiolabelled GSK189075
|
| Outcome Measures: |
Primary: Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5., at Days 1-5.|Urine & Fecal collection at Day -1 & days 1-5., at Day -1 & days 1-5. | Secondary: Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days, at each day for up to 10 days
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
8
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-11
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2012-06-04
|
| Locations: |
GSK Investigational Site, Madison, Wisconsin, 53704, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00501683
|
